Investors Press Releases Oct 16 2026 Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease Read More Sep 30 2026 Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA) Read More Sep 28 2026 Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab Read More btn News View All Events & Presentations More events are coming soon. btn Events View All Interim Reports Interim Results for the Six Months Ended 30 June 2026 758.9 KB bth Interim Reports View All Annual Reports 20 F - Annual Report for the year ended 31 December 2025 2 MB btn ARs View All Annual General Meeting 2025 AGM Results 60.5 KB btn AGM View All Stock Quote Change Volume Today's Open Previous Close Today's High Today's Low 52 Week High 52 Week Low Stock Chart
Oct 16 2026 Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease Read More
Sep 30 2026 Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA) Read More
Sep 28 2026 Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab Read More